Desensitization to protein kinase inhibitors

Cancer is responsible for more than half a million American deaths every year and an estimated 39% of men and women will be diagnosed with at least 1 type of cancer during their lifetime.1 Cytotoxic agents were previously the mainstay of therapy and continue to be used frequently in oncology practice, but their nonspecific mechanism of action is associated with extensive adverse effect profiles. The development of "targeted" therapies in the form of biologic agents and protein kinase inhibitors (PKIs) revolutionized cancer treatment and dominate the oncology drug pipeline.

http://ift.tt/2sgfRSa